News
Schering: Serono bedrängt die Berliner - manager magazin
www.manager-magazin.de
Der Umsatzbringer Betaferon bekommt Konkurrenz. Analysten bleiben jedoch gelassen.
Bayer and Bristol's rival clot drugs both impress - EcoDiario.es
www.eleconomista.es
If Pradaxa gets FDA approval, I don't see why Xarelto shouldn't," said LBBW analyst Karl-Heinz Scheunemann. Bayer shares were 2.5 percent ...
Des risques juridiques liés aux OGM sapent les RTL infowww.rtl.be › ... › Economie
www.rtl.be
... à la provision de 436 millions d'euros pour des risques juridiques aux Etats-Unis, a relevé Karl-Heinz Scheunemann, analyste chez LBBW.
Bayer, J&J stroke drug not ready for approval: FDA | Reuters
www.reuters.com
Drug regulators said an experimental stroke preventer from Bayer and Johnson & Johnson is not ready for approval and raised questions about its effectiveness,...
sortiert nach Relevanz / Datum